Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 12, 2011, Pages 4938-4943

  Takahashi, Sayuri ^a,b   Watanabe, Tomoyuki ^a   Okada, Maiko ^a,b   Inoue, Kazuki ^a   Ueda, Takashi ^a,c   Takada, Ichiro ^a,b   Watabe, Tetsuro ^d   Yamamoto, Yoko ^a   Fukuda, Toru ^a   Nakamura, Takashi ^a,b   Akimoto, Chihiro ^a   Fujimura, Tetsuya ^a   Hoshino, Maiko ^a   Imai, Yuuki ^a   Metzger, Daniel ^e   Miyazono, Kohei ^d   Minami, Yasuhiro ^f   Chambon, Pierre ^e   Kitamura, Tadaichi ^a   Matsumoto, Takahiro ^a,b,g   Kato, Shigeaki ^a,b   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^f KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Antiandrogen; Hormone refractory state; TRAMP

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ESTROGEN; WNT PROTEIN; WNT5A PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENE LOCUS; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; SOMATIC MUTATION; TUMOR GROWTH; UPREGULATION;

AMINO ACID SUBSTITUTION; ANDROGENS; ANIMALS; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; POINT MUTATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; WNT PROTEINS;

MUS; MUS MUSCULUS;

EID: 79953213352     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1014850108     Document Type: Article

References (48)

1. De Marzo AM, et al. (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256-269. (Pubitemid 46486616)
2. Hsieh AC, Small EJ, Ryan CJ (2007) Androgen-response elements in hormone-refractory prostate cancer: Implications for treatment development. Lancet Oncol 8:933-939. (Pubitemid 47488068)
3. Denmeade SR, Isaacs JT (2002) A history of prostate cancer treatment. Nat Rev Cancer 2:389-396. (Pubitemid 37328952)
4. Ross RW, et al. (2008) Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: Association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 112:1247-1253. (Pubitemid 351429739)
5. Prostate Cancer Trialists Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 355:1491-1498.
6. Scholz M, et al. (2007) Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosteronein-activating pharmaceuticals. Urology 70:506-510. (Pubitemid 47464488)
7. Oudard S, et al. (2007) New targeted therapies in hormone-refractory prostate cancer. Bull Cancer 94(7 Suppl):F62-F68. (Pubitemid 47242313)
8. Lilja H, Ulmert D, Vickers AJ (2008) Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer 8:268-278. (Pubitemid 351430866)
9. Mangelsdorf DJ, et al. (1995) The nuclear receptor superfamily: The second decade. Cell 83:835-839.
10. Norris JD, et al. (2009) The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell 36:405-416.
11. Wang Q, et al. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245-256.
12. Glass CK, Rosenfeld MG (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121-141. (Pubitemid 30070977)
13. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT (2005) Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 102:6201-6206. (Pubitemid 40594278)
14. Yoshida T, et al. (2005) Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 65:9611-9616. (Pubitemid 41541433)
15. Taplin ME, et al. (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398.
16. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45. (Pubitemid 33741879)
17. Sun C, et al. (2006) Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 25:3905-3913. (Pubitemid 43990745)
18. Suzuki H, et al. (1996) Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: Relation to antiandrogen withdrawal syndrome. Prostate 29:153-158. (Pubitemid 26341820)
19. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41-51. (Pubitemid 46020826)
20. Zhu P, et al. (2006) Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124:615-629. (Pubitemid 43199445)
21. Ahmad I, Sansom OJ, Leung HY (2008) Advances in mouse models of prostate cancer. Expert Rev Mol Med 10:e16.
22. Masumori N, et al. (2001) A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 61:2239-2249. (Pubitemid 32692054)
23. Ratnacaram CK, et al. (2008) Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc Natl Acad Sci USA 105:2521-2526. (Pubitemid 351520546)
24. Kawano H, et al. (2003) Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA 100:9416-9421. (Pubitemid 37033943)
25. Sato T, et al. (2003) Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochem Biophys Res Commun 300:167-171. (Pubitemid 36042946)
26. Mooradian AD, Morley JE, Korenman SG (1987) Biological actions of androgens. Endocr Rev 8:1-28.
27. Nakamura T, et al. (2007) Estrogen prevents bone loss via estrogen receptor α and induction of Fas ligand in osteoclasts. Cell 130:811-823. (Pubitemid 47332572)
28. Brinkmann AO, Trapman J (2000) Prostate cancer schemes for androgen escape. Nat Med 6:628-629. (Pubitemid 30398780)
29. He HH, et al. (2010) Nucleosome dynamics define transcriptional enhancers. Nat Genet 42:343-347.
30. Jia L, et al. (2008) Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One 3:e3645.
31. Kwong J, Xuan JW, Chan PS, Ho SM, Chan FL (2000) A comparative study of hormonal regulation of three secretory proteins (prostatic secretory protein-PSP94, probasin, and seminal vesicle secretion II) in rat lateral prostate. Endocrinology 141:4543-4551. (Pubitemid 32055132)
32. Sekine K, et al. (1999) Fgf10 is essential for limb and lung formation. Nat Genet 21: 138-141. (Pubitemid 29036301)
33. Takada I, et al. (2007) A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-γ transactivation. Nat Cell Biol 9:1273-1285. (Pubitemid 350042359)
34. Yamaguchi TP, Bradley A, McMahon AP, Jones S (1999) A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development 126:1211-1223. (Pubitemid 29182117)
35. Katoh M, Katoh M (2007) STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer. Int J Mol Med 19:273-278.
36. Sanjo H, et al. (2003) TAB2 is essential for prevention of apoptosis in fetal liver but not for interleukin-1 signaling. Mol Cell Biol 23:1231-1238. (Pubitemid 36177033)
37. Wang S, et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4:209-221. (Pubitemid 37163835)
38. Chen CD, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39. (Pubitemid 38524696)
39. Fukuda T, et al. (2007) DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. Nat Cell Biol 9:604-611. (Pubitemid 46696543)
40. Donehower LA, Lozano G (2009) 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 9:831-841.
41. Shay JW, Wright WE (2002) Telomerase: A target for cancer therapeutics. Cancer Cell 2:257-265. (Pubitemid 41043959)
42. Lei Q, et al. (2006) NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9:367-378. (Pubitemid 43668733)
43. Sun X, et al. (2005) Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet 37:407-412.
44. Veeman MT, Axelrod JD, Moon RT (2003) A second canon. Functions and mechanisms of β-catenin-independent Wnt signaling. Dev Cell 5:367-377.
45. Takada I, Kouzmenko AP, Kato S (2009) Wnt and PPARγ signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 5:442-447.
46. McDonald SL, Silver A (2009) The opposing roles of Wnt-5a in cancer. Br J Cancer 101: 209-214.
47. Pukrop T, Binder C (2008) The complex pathways of Wnt 5a in cancer progression. J Mol Med 86:259-266. (Pubitemid 351311422)
48. Yoshizawa T, et al. (1997) Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 16: 391-396. (Pubitemid 27323308)